Green Cross develops fourth natural medicine

Published: 2011-01-27 07:00:00

Updated: 2011-01-27 07:00:00

Green Cross Corp. says its natural drug for the treatment of osteoarthritis drug ‘Shinbaro’ has been recently approved by the Korea Food and Drug Administration.

The company said Shinbaro is Korea’s fourth homegrown natural medicine, which have been developed through the intensive studies for ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK